Headlines about Esperion Therapeutics (NASDAQ:ESPR) have trended positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.28 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.8896774350781 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern’s scoring:

Esperion Therapeutics (NASDAQ ESPR) traded down 0.39% on Wednesday, reaching $48.08. The company had a trading volume of 761,308 shares. The firm has a 50 day moving average price of $47.12 and a 200-day moving average price of $37.64. The stock’s market capitalization is $1.09 billion. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the company earned ($0.62) EPS. Analysts forecast that Esperion Therapeutics will post ($7.33) earnings per share for the current fiscal year.

A number of equities research analysts have recently issued reports on the company. Northland Securities assumed coverage on Esperion Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $72.00 target price on the stock. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st. Bank of America Corporation reaffirmed a “neutral” rating and set a $60.00 target price on shares of Esperion Therapeutics in a research report on Friday, August 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 target price (up from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $48.89.

COPYRIGHT VIOLATION NOTICE: “Positive Media Coverage Somewhat Unlikely to Impact Esperion Therapeutics (ESPR) Share Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/positive-media-coverage-somewhat-unlikely-to-impact-esperion-therapeutics-espr-share-price/1532526.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.